Cargando…

Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)

Immunotherapy has considerably changed the treatment of lung cancer. As immunotherapy has a special mechanism of action, the disease remission that it can induce is unique. Recently, Immune Response Evaluation Criteria in Solid Tumors (iRECIST), which focus on assessing the apparent curative effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Peng, Zhang, Jingcheng, Shang, Congcong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449267/
https://www.ncbi.nlm.nih.gov/pubmed/30779329
http://dx.doi.org/10.1111/1759-7714.13010
_version_ 1783408806329319424
author Song, Peng
Zhang, Jingcheng
Shang, Congcong
Zhang, Li
author_facet Song, Peng
Zhang, Jingcheng
Shang, Congcong
Zhang, Li
author_sort Song, Peng
collection PubMed
description Immunotherapy has considerably changed the treatment of lung cancer. As immunotherapy has a special mechanism of action, the disease remission that it can induce is unique. Recently, Immune Response Evaluation Criteria in Solid Tumors (iRECIST), which focus on assessing the apparent curative effect of immunotherapy, have become widely accepted. Based on iRECIST criteria, if the response to immunotherapy is determined to be immunity‐confirmed progressive disease or immunity‐unconfirmed progressive disease, and the Eastern Cooperative Oncology Group score is worse than before treatment, immunotherapy should be discontinued. We report two immunity‐confirmed progressive disease cases after pembrolizumab treatment and one immunity‐unconfirmed progressive disease case after nivolumab treatment. All three patients benefited from continued immunotherapy, which indicates that the iRECIST criteria may have limitations in assessing the efficacy of immunotherapy for non‐small cell lung cancer patients.
format Online
Article
Text
id pubmed-6449267
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-64492672019-04-15 Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST) Song, Peng Zhang, Jingcheng Shang, Congcong Zhang, Li Thorac Cancer Mini Review Immunotherapy has considerably changed the treatment of lung cancer. As immunotherapy has a special mechanism of action, the disease remission that it can induce is unique. Recently, Immune Response Evaluation Criteria in Solid Tumors (iRECIST), which focus on assessing the apparent curative effect of immunotherapy, have become widely accepted. Based on iRECIST criteria, if the response to immunotherapy is determined to be immunity‐confirmed progressive disease or immunity‐unconfirmed progressive disease, and the Eastern Cooperative Oncology Group score is worse than before treatment, immunotherapy should be discontinued. We report two immunity‐confirmed progressive disease cases after pembrolizumab treatment and one immunity‐unconfirmed progressive disease case after nivolumab treatment. All three patients benefited from continued immunotherapy, which indicates that the iRECIST criteria may have limitations in assessing the efficacy of immunotherapy for non‐small cell lung cancer patients. John Wiley & Sons Australia, Ltd 2019-02-19 2019-04 /pmc/articles/PMC6449267/ /pubmed/30779329 http://dx.doi.org/10.1111/1759-7714.13010 Text en © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Mini Review
Song, Peng
Zhang, Jingcheng
Shang, Congcong
Zhang, Li
Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
title Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
title_full Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
title_fullStr Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
title_full_unstemmed Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
title_short Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
title_sort curative effect assessment of immunotherapy for non‐small cell lung cancer: the “blind area” of immune response evaluation criteria in solid tumors (irecist)
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449267/
https://www.ncbi.nlm.nih.gov/pubmed/30779329
http://dx.doi.org/10.1111/1759-7714.13010
work_keys_str_mv AT songpeng curativeeffectassessmentofimmunotherapyfornonsmallcelllungcancertheblindareaofimmuneresponseevaluationcriteriainsolidtumorsirecist
AT zhangjingcheng curativeeffectassessmentofimmunotherapyfornonsmallcelllungcancertheblindareaofimmuneresponseevaluationcriteriainsolidtumorsirecist
AT shangcongcong curativeeffectassessmentofimmunotherapyfornonsmallcelllungcancertheblindareaofimmuneresponseevaluationcriteriainsolidtumorsirecist
AT zhangli curativeeffectassessmentofimmunotherapyfornonsmallcelllungcancertheblindareaofimmuneresponseevaluationcriteriainsolidtumorsirecist